TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03761108: Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 387 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$8,600,130

Rescue Site Savings

+$5,694,150

Unlock Full NCT03761108 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03761108 Rescue Dossier →